Cargando…
CH-01 is a Hypoxia-Activated Prodrug That Sensitizes Cells to Hypoxia/Reoxygenation Through Inhibition of Chk1 and Aurora A
[Image: see text] The increased resistance of hypoxic cells to all forms of cancer therapy presents a major barrier to the successful treatment of most solid tumors. Inhibition of the essential kinase Checkpoint kinase 1 (Chk1) has been described as a promising cancer therapy for tumors with high le...
Autores principales: | Cazares-Körner, Cindy, Pires, Isabel M., Swallow, I. Diane, Grayer, Samuel C., O’Connor, Liam J., Olcina, Monica M., Christlieb, Martin, Conway, Stuart J., Hammond, Ester M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American
Chemical Society
2013
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3719478/ https://www.ncbi.nlm.nih.gov/pubmed/23597309 http://dx.doi.org/10.1021/cb4001537 |
Ejemplares similares
-
Antibody-Based Imaging of Bioreductive Prodrug Release
in Hypoxia
por: Tosun, Çağla, et al.
Publicado: (2023) -
ATM activation in hypoxia - causes and consequences
por: Olcina, Monica M, et al.
Publicado: (2014) -
Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition
por: Meng, Fanying, et al.
Publicado: (2015) -
The hypoxia–reoxygenation stress in plants
por: León, José, et al.
Publicado: (2020) -
Targeting Hypoxia: Hypoxia-Activated Prodrugs in Cancer Therapy
por: Li, Yue, et al.
Publicado: (2021)